A powerful approach

We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options.

Development Pipeline

Patient Selection
Clinical Trials
MTAP-del cancers
Phase 1/2
Phase 3
Dose expansion ongoing, clinical data in 2H 2024
Phase 1/2
Patients: MTAP-del cancers
Anticipated Milestones: Dose expansion ongoing, clinical data in 2H 2024

Our Phase 1/2 first-in-human trial to evaluate TNG908 in patients with MTAP-deleted tumors is being conducted in two parts. The dose escalation phase in patients with locally advanced or metastatic cancer of any histology with an MTAP deletion has been completed and we are now entering the dose expansion portion of the trial at 600 mg BID.

MTAP-del cancers
Dose expansion planned 2Q 2024; clinical data 2H 2024
Phase 1/2
Patients: MTAP-del cancers
Anticipated Milestones: Dose expansion planned 2Q 2024; clinical data 2H 2024

TNG462 is actively enrolling patients in the Phase 1/2 trial. The clinical development path is similar to TNG908, evaluating safety and efficacy in multiple tumor types. Glioblastoma will be excluded from the Phase 1/2 trial as TNG462 does not cross the blood-brain barrier in preclinical models.

STK11-mut cancers
Dose escalation ongoing
Phase 1/2
Patients: STK11-mut cancers
Anticipated Milestones: Dose escalation ongoing

The TNG260 clinical development plan will be among the first to combine the power of genetic patient selection and immunotherapy. TNG260 is in the dose escalation portion of a Phase 1/2 trial, being evaluated in combination with pembrolizumab for the treatment of STK11-mutant cancers.

Multiple synthetic lethal targets
Tumor suppressor gene loss

Gilead optioned and licensed targets not listed – learn more about our partnership below


Our global strategic collaboration with Gilead Sciences is focused on the discovery, development and commercialization of a pipeline of innovative targeted immune evasion therapies for patients with cancer. We are responsible for discovering and validating targets and for advancing select programs through clinical proof-of-concept. Gilead has options to worldwide rights on up to 15 of those targets. We retain the option to co-develop and co-promote the lead products for up to five of those programs in the U.S. with Gilead.

The collaboration, which was originally signed in 2018 and expanded in 2020, does not include our three lead programs. We retain all rights to those programs, along with the right to targets we have identified outside of the immune evasion space. We are committed to advancing the programs in our wholly owned pipeline into the clinic and beyond, as part of our mission to deliver the next generation of transformational targeted therapies to patients in need.

Tango Therapeutics Gilead

The Gilead logo is a trademark of Gilead Sciences, Inc.

We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: bd@tangotx.com.

Learn more about the culture of innovation at Tango.Learn more about the culture of innovation at Tango.